Literature DB >> 11841438

Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level.

James O'Donnell1, Frank E Boulton, Richard A Manning, Michael A Laffan.   

Abstract

Previous reports on the effect of Secretor and Lewis blood groups on plasma factor VIII-von Willebrand factor (FVIII-VWF) levels have produced conflicting findings. To determine whether either or both loci can influence plasma FVIII-VWF complex levels, we studied the relationship between Secretor and Lewis genotypes, determined definitively using polymerase chain reaction-restriction fragment length polymorphism analysis, and plasma FVIII coagulant activity (FVIII:C) and VWF antigen (VWF:Ag) levels in 136 healthy volunteers. Overall, significantly higher VWF:Ag levels were found in those individuals homozygous for the Se allele (genotype SeSe) than in those heterozygous for the Se allele (P < 0.001). To minimize any confounding influence of ABO genotype/phenotype, we investigated the relationship between Secretor genotype and plasma FVIII-VWF levels within individuals of the same ABO blood group genotype. In the subgroup analysis of group O1O1 individuals alone, VWF:Ag levels were again significantly higher in those individuals with Secretor genotype SeSe than in those either heterozygous or homozygous for the se null allele. Among A1O1 subjects, homozygous Secretors also had significantly higher VWF:Ag levels. In contrast, we found no relationship between Lewis genotype and either VWF:Ag or FVIII:C levels. This study is the first based on genotypic rather than serological analysis, and resolves the previously confounding effects of the Lewis and Secretor loci on plasma FVIII-VWF complex levels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841438     DOI: 10.1046/j.1365-2141.2002.03270.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium.

Authors:  Brian M Wolpin; Peter Kraft; Mousheng Xu; Emily Steplowski; Martin L Olsson; Alan A Arslan; H Bas Bueno-de-Mesquita; Myron Gross; Kathy Helzlsouer; Eric J Jacobs; Andrea LaCroix; Gloria Petersen; Rachael Z Stolzenberg-Solomon; Wei Zheng; Demetrius Albanes; Naomi E Allen; Laufey Amundadottir; Melissa A Austin; Marie-Christine Boutron-Ruault; Julie E Buring; Federico Canzian; Stephen J Chanock; J Michael Gaziano; Edward L Giovannucci; Göran Hallmans; Susan E Hankinson; Robert N Hoover; David J Hunter; Amy Hutchinson; Kevin B Jacobs; Charles Kooperberg; Julie B Mendelsohn; Dominique S Michaud; Kim Overvad; Alpa V Patel; Maria-José Sanchéz; Leah Sansbury; Xiao-Ou Shu; Nadia Slimani; Geoffrey S Tobias; Dimitrios Trichopoulos; Paolo Vineis; Kala Visvanathan; Jarmo Virtamo; Jean Wactawski-Wende; Joanne Watters; Kai Yu; Anne Zeleniuch-Jacquotte; Patricia Hartge; Charles S Fuchs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-22       Impact factor: 4.254

2.  Selection on cis-regulatory variation at B4galnt2 and its influence on von Willebrand factor in house mice.

Authors:  Jill M Johnsen; Meike Teschke; Pavlos Pavlidis; Beth M McGee; Diethard Tautz; David Ginsburg; John F Baines
Journal:  Mol Biol Evol       Date:  2008-12-16       Impact factor: 16.240

3.  Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association.

Authors:  Karl C Desch; Ayse B Ozel; David Siemieniak; Yossi Kalish; Jordan A Shavit; Courtney D Thornburg; Anjali A Sharathkumar; Caitlin P McHugh; Cathy C Laurie; Andrew Crenshaw; Daniel B Mirel; Yoonhee Kim; Cheryl D Cropp; Anne M Molloy; Peadar N Kirke; Joan E Bailey-Wilson; Alexander F Wilson; James L Mills; John M Scott; Lawrence C Brody; Jun Z Li; David Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-24       Impact factor: 11.205

Review 4.  Genetic regulation of plasma von Willebrand factor levels in health and disease.

Authors:  L L Swystun; D Lillicrap
Journal:  J Thromb Haemost       Date:  2018-10-30       Impact factor: 5.824

5.  Higher frequency of secretor phenotype in O blood group - its benefits in prevention and/or treatment of some diseases.

Authors:  Mohamad Salih Jaff
Journal:  Int J Nanomedicine       Date:  2010-11-02

Review 6.  Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia.

Authors:  Peter L Turecek; Jill M Johnsen; Steven W Pipe; James S O'Donnell
Journal:  Haemophilia       Date:  2020-06-28       Impact factor: 4.287

Review 7.  The relationship between ABO blood group, von Willebrand factor, and primary hemostasis.

Authors:  Soracha E Ward; Jamie M O'Sullivan; James S O'Donnell
Journal:  Blood       Date:  2020-12-17       Impact factor: 22.113

8.  X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers.

Authors:  Isabella Garagiola; Mimosa Mortarino; Simona Maria Siboni; Marco Boscarino; Maria Elisa Mancuso; Marina Biganzoli; Elena Santagostino; Flora Peyvandi
Journal:  Eur J Hum Genet       Date:  2020-10-20       Impact factor: 4.246

9.  Blood group type A secretors are associated with a higher risk of COVID-19 cardiovascular disease complications.

Authors:  Tosti J Mankelow; Belinda K Singleton; Pedro L Moura; Christian J Stevens-Hernandez; Nicola M Cogan; Gyongyver Gyorffy; Sabine Kupzig; Luned Nichols; Claire Asby; Jennifer Pooley; Gabriella Ruffino; Faroakh Hosseini; Fiona Moghaddas; Marie Attwood; Alan Noel; Alex Cooper; David T Arnold; Fergus Hamilton; Catherine Hyams; Adam Finn; Ashley M Toye; David J Anstee
Journal:  EJHaem       Date:  2021-04-02

10.  Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications.

Authors:  Massimo Franchini; Franco Capra; Giovanni Targher; Martina Montagnana; Giuseppe Lippi
Journal:  Thromb J       Date:  2007-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.